
    
      The costs will be assessed by micro-costing approach. All procedures involved in lung cancer
      at diagnosis, staging, treatment and best supportive care will be assessed.

      The health-related quality of life will be assessed by EORTC-QLQ-C30, EQ-5D and
      EORTC-QLQ-LC13 in all different stages of lung cancer.

      An utility measure will be considered. The preference values will be assessed via discrete
      choice experiment. Two scenarios will be designed and the lung cancer patients will be asked
      about the preferences.
    
  